Intensive chemotherapy failure in Burkitt’s lymphoma with cavernous sinus involvement

2009 ◽  
Vol 27 (2) ◽  
pp. 327-331 ◽  
Author(s):  
Zhi-Yu Chen ◽  
Bin Wu ◽  
Ji-Liang Yin
Keyword(s):  
Cavernous Sinus ◽  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma ◽  
Intensive Chemotherapy

Cavernous sinus syndrome as the initial symptom of Burkitt's lymphoma

2021 ◽  
Author(s):  
A. Aramburu-González ◽  
P. Rivera-Pérez De Rada ◽  
L. Antón-Méndez ◽  
M. Cisneros-Carpio ◽  
O. Arce-Fernández
Keyword(s):  
Cavernous Sinus ◽  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma ◽  
Initial Symptom ◽  
Cavernous Sinus Syndrome

scholarly journals Intensive chemotherapy for non-localised Burkitt's lymphoma.

1986 ◽  
Vol 61 (10) ◽  
pp. 1013-1019 ◽  
Author(s):  
A Al-Attar ◽  
J Pritchard ◽  
T Al-Saleem ◽  
M Al-Naimi ◽  
N Alash ◽  
...  
Keyword(s):  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma ◽  
Intensive Chemotherapy

scholarly journals Burkitt’s Lymphoma with Bilateral Cavernous Sinus Involvement: A Case Report

JMED Research ◽  
2016 ◽  
pp. 1-7 ◽  
Author(s):  
Monique Boukobza ◽  
Jean-Philippe Brouland
Keyword(s):  
Case Report ◽  
Cavernous Sinus ◽  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma

Comparison of CHOP treatment with specific short-intensive chemotherapy in AIDS-related Burkitt's lymphoma or leukemia

2011 ◽  
Vol 136 (8) ◽  
pp. 323-328 ◽  
Author(s):  
Blanca Xicoy ◽  
Josep María Ribera ◽  
Pilar Miralles ◽  
José La Cruz ◽  
Albert Oriol ◽  
...  
Keyword(s):  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma ◽  
Intensive Chemotherapy

Intensive chemotherapy in patients with generalized Burkitt's lymphoma

1972 ◽  
Vol 10 (2) ◽  
pp. 254-261 ◽  
Author(s):  
John L. Ziegler ◽  
Avrum Z. Bluming ◽  
Ian T. Magrath ◽  
Paul P. Carbone
Keyword(s):  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma ◽  
Intensive Chemotherapy

Intensive Chemotherapy (LMB-86 Regimen) for AIDS-Related Burkitt’s Lymphoma/Leukemia.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 924-924
Author(s):  
Lionel Galicier ◽  
Claire Fieschi ◽  
Laurence Gerard ◽  
Sylvie Chevrey ◽  
Emmanuelle Boulanger ◽  
...  
Keyword(s):  
Chemotherapy Regimen ◽  
Univariate Analysis ◽  
Bone Marrow Involvement ◽  
Disease Free Survival ◽  
Stage Iv ◽  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma ◽  
High Dose ◽  
Induction Phase ◽  
Intensive Chemotherapy

Abstract Early studies report extremely poor outcome in AIDS-related Burkitt’s lymphoma treated with standard dose chemotherapy. This poor prognosis is not improved by Highly Active Antiretroviral Therapy (HAART). 53 patients with HIV infection and stage IV Burkitt lymphoma/leukemia (BL) participated a unicentric and prospective clinical trial to evaluate the safety and efficacy of the intensive LMB-86 chemotherapy regimen. The median CD4 cell count was 236 x 106/l. 32 tumors were of the Burkitt type and 21 were Burkitt-like. All patients had stage IV disease with bone marrow involvement in 40 and central nervous system disease in 37. The LMB-86 regimen combined: (1) cytoreductive phase, with low dose cyclophosphamide, vincristine and steroids; (2) induction phase, with 2 consecutive courses of COPADM with high dose (8 g/m2) methotrexate (MTX); (3) consolidation phase with two courses of CYVE with high dose cytarabine and etoposide; (4) maintenance phase, with four courses combining previous drugs with lower dosage. Thirty eight patients (71.7 %) achieved complete remission after the induction phase. With a median follow-up of 74.1 months (range, 8–153.1), 11 have progressed on therapy or relapsed. The median survival was 14.2 months and 32 patients have died. Most of deaths were due to BL (n=17, 53.1%), 5 (15.6%) to treatment toxicity, 7 (21.9%) to AIDS and 3 (9.4%) to other causes. The 1-year and 2-year estimate survival were 51% (95% CI, 44.1%–57.9%) and 47% (95% CI, 40.1%–53.9%), respectively (figure). Median disease free survival (DFS) was 41.7 months (range, 11.5-not reached) with a 2-year estimate DFS of 59.3%. Using the univariate analysis, four baseline covariates were associated with shorter survival: CD4<200 x 106/L (HR 3.3; 95% IC, 1.6–6.6), CD8 <1500 x 106/L (HR 2.5; 95% IC, 1.1–10), "B" symptoms (HR 3.6; 95% IC, 1.1–11.9), and ECOG score > 2 (HR 2.9, 95% IC, 1.3–6.4). No other HIV covariates, lymphoma baseline data or demographic data were associated with outcome. Using multivariate analysis only association with low CD4 count was significant (p=0.03). Intensive chemotherapy regimen (LMB-86) containing high dose MTX and cytarabine is highly efficient in stage IV AIDS-related Burkitt’s lymphoma. Toxicity is high but acceptable with regard to the best overall survival reported to date. Figure Figure

scholarly journals Burkitt's lymphoma with bilateral cavernous sinus and mediastinal involvement in a child

2003 ◽  
Vol 33 (10) ◽  
pp. 719-721 ◽  
Author(s):  
Thierry A. G. M. Huisman ◽  
Frank Tschirch ◽  
Jacques F. L. Schneider ◽  
Felix Niggli ◽  
Ernst Martin-Fiori ◽  
...  
Keyword(s):  
Cavernous Sinus ◽  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma ◽  
Mediastinal Involvement
Sign in / Sign up

Export Citation Format

Share Document